Back

Comparison of clinical and economic burden of pulmonary arterial hypertension patients with and without connective tissue disease treated with macitentan

28 August 2022 (13:15 - 13:45)
Organised by:
Congress Presentation Part of: Hypertension - Treatment lifestyle and pharmacotherapy Treatment ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Carly Worden

Janssen Pharmaceuticals, Titusville (United States of America)

4 More presentations in this session

Presentation thumbnail
Persistence with macitentan versus other endothelin receptor antagonists in patients with pulmonary arterial hypertension: experience from a real-world data repository in the USA
Doctor S. Panjabi (San Mateo, US)
Abstract Slides
Presentation thumbnail
Additional opportunities for antihypertensive therapy improvement in young patients with arterial hypertension and concomitant obesity
Doctor K. Chernyshova (Odessa, UA)
Abstract Slides
Presentation thumbnail
The music therapy effectiveness in hypertensive patients with acute myocardial infarction after previous coronary artery bypass surgery; 18-year experience of the MUSIC study
Professor P. Mitrovic (Belgrade, RS)
Abstract Slides
Presentation thumbnail
Angiotensin receptor blockers are equally effective in women and men; a systematic review and meta-analysis
Mrs S. Laven (Maastricht, NL)
Abstract Slides

Access the full session

Session thumbnail
Hypertension - Treatment lifestyle and pharmacotherapy

The Event

Event poster

ESC Congress 2022

28 August 2022 13:15 CET
You may be interested in
thumbnail
Congress Session
Arterial hypertension
thumbnail
Congress Presentation
What is new in hypertension: highlights from the 2024 ESC Guidelines for the Management of Elevated Blood Pressure and Hypertension
thumbnail
Congress Presentation
Add-on treatment with zilebesiran for inadequately controlled hypertension: KARDIA-2 RCT

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources